Oncology treatments are still too frequently ineffective, while in parallel technological advances allow the classification of new cancer subtypes using molecular and cellular analyses.
The cancer-related mortality is expected to increase by more than 50% between 2002 and 2030, with about 11.5 million deaths in 2030 worldwide
The costs of cancer worldwide reached nearly $ 80 billion in 2014
Building a sustainable sector and accelerate the discovery of new treatments tailored to each patient.
IMODI partners are organized within a consortium owned by both private and public pharmaceutical and medical research labs, creating a unique chain of value and expertises from the patient to the therapeutic target.
In addition to awareness of each partner, this structuring project has received recognition from 5 French competitiveness poles: Medicen, Alsace BioValley, Cancer Bio Santé, Lyon Biopole and Atlanpôle Biotherapy . Moreover, IMODI is granted by the French government with the financial support of the Public Investment Bank as part of the “Avenir Investment Program” .
The founder and coordinator of this consortium is OncoDesign, a French SME company, based in Dijon. OncoDesign has been created in 1995 by its current CEO Dr. Philippe Genne.
- Accelerate the discovery of new treatments
- Increase the effectiveness of new treatments
- Reduce failures in clinical trials
- Improve patient stratification for better personalization of treatments
IMODI is an industrial sector of health, answering to the needs of the scientific and medical community, whether private or public. Its construction was initiated in 2013.
Experimental models: The center of IMODI strategyExperimental models constitute a highly strategic step between new drug candidates and patients. In this context there is a need to develop new experimental models of cancer mimicking as close as possible the human pathology. These models represent powerful tools for translation to humans when they are accompanied by a comprehensive characterization, including the patient's clinical history, the tumor histology, as well as the molecular profiles and the pharmacological sensitivity.
As a practical matter, work is organized around 3 major R&D axes:
- Developing in vivo models and cell-based assays
- Mimicking the human biology by humanizing the tumor microenvironment in mice
- Studying the microbiota in cancer patients
The main deliverables expected for this first phase of developments (2013-2019) are:
- Development of 2D & 3D ex vivo phenotypic assays
- Development and characterization of mouse models with the humanization of the immune system, hepatic system and tumor stroma
- Establishment of a centralized biobank for the conservation of tumor samples, blood cells, serum and stools
- Characterization of the gut microbiota from patients and PDX models
- Development of a Database combining both preclinical and clinical information associated with models and make them available to the public and private scientific community
- Development of data mining tools
Strengths and operating rules
- Medical and industrial vision of unmet needs in oncology
- Selection of cancer pathologies based on both clinical and pharmaceutical needs
- Industrial standards applied to all value creation chain (ethics, quality, technology ...)
- Unique central storage of biological samples and data
- Centralized management of intellectual / industrial properties
- A sustainable economic system based on the activity and development of the operating SMEs knowledge & know-how
- Freedom to use the IMODI results for internal R&D of the members
- A strong cross-fertilization between active members